-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
02 Jul 2024 11:25 CEST
Issuer
SARTORIUS STEDIM BIOTECH
|
Sartorius Stedim Biotech SA
Aubagne, July 2nd, 2024
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2024:
As a reminder : The following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:
The following resources appeared on the liquidity account when the activity started:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 Petra.mueller2@sartorius.com
Sartorius Stedim Biotech S.A. Z.I. Les Paluds Avenue de Jouques, CS 91051 13781 Aubagne Cedex, France Phone: +33.(0)4.42.84.56.00 Fax: +33.(0)4.42.84.56.19 www.sartorius.com
Regulatory filing PDF file File: Sartorius Stedim Biotech_half-year report on liquidity contract_20240630 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Share buyback / Disposal of own shares / Information relating to the liquidity contract |
| EQS News ID: | 1937983 |
| End of Announcement | EQS News Service |
1937983 02-Jul-2024 CET/CEST
Source
Sartorius Stedim Biotech SA
Provider
EQS Group
Company Name
SARTORIUS STED BIO, SARTORIUS STEDIM BIOTECH
ISIN
FR0013154002, FR0013154002
Symbol
DIM, 4DIM
Market
Euronext